Clinical Trial Update: Stem Cell Implantation in Patients Undergoing CABG [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating stem cell implantation in patients undergoing CABG was terminated; Miltenyi Biotec is the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Cardiomyopathy

Drugs mentioned

• Stem cell implantation (cell therapy)

Snippet

Sponsor: Miltenyi Biotec, Inc. | Conditions: Ischemic Cardiomyopathy, Coronary Artery Disease | Phase 1 | Status: TERMINATED